世界农化网中文网报道：2026年5月31日，河南美利宝农业科技有限公司联合南京农业大学，组织一众权威专家，对南京农业大学在南京市浦口区桥林街道兰花塘（丽阳晨农业种植公司种植基地）实施的稻茬小麦喷施″黑能量增产肥″试验示范田开展现场实收测产。本次测产专家团队阵容权威，由南京农业大学姜东教授、周琴教授领衔，扬州大学、江苏省粮食作物现代产业技术协同创新中心、江苏省农业科学院、江苏里下河地区农业科学研究所、南京市农业技术推广站、南京市浦口区农业农村局等多家科研与农技推广单位专家共同参与，全程见证田间实收测产全过程，以标准化测产流程核验产品提质增产实效。

China’s new framework for advanced biomedical technologies could reshape how cell and gene therapies (CGTs) reach patients in one of the world’s most active biotech markets. State Council Order No. 818 took effect on May 1, 2026, and establishes China’s first national framework for the clinical research and translational application of new biomedical technologies, including cell therapies, gene therapies, gene editing, stem cell technologies, tissue engineering, and other emerging medical approaches.  

The biotech, which has a presence in Germany and Texas, has built a pipeline on preferentially expressed antigen in melanoma (PRAME). The cancer-testis antigen is broadly expressed in solid tumors, providing Immatics with chances to treat a range of diseases including cutaneous melanoma, uterine carcinoma and synovial sarcoma.

“Specialty crop growers are looking for practical, scalable automation technologies that can help them be more sustainable, efficient and profitable today, while also preparing for the future”, says Yamaha Agriculture President and CEO Nolan Paul.

Two years after emerging from bankruptcy, biomanufacturing specialist Amyris is not yet profitable, but is a “drasticall…

The Zug-based company said the DIAMOND-1 and DIAMOND-2 trials did not show a statistically meaningful improvement in best corrected visual acuity after 52 weeks of treatment compared with vehicle. The result is particularly damaging because visual acuity was the primary endpoint of the programme and the basis for a potential regulatory filing.

High-resolution extracellular electrophysiology is typically used to record from neurons in order to understand brain function. Combining electrophysiology with optogenetics allows researchers to test the causal role of specific neurons by activating or inactivating those populations while recording the effects of neural activity.

Under the agreement, Servier will pay US$1.55bn upfront and up to US$1.1bn in regulatory and commercial milestones. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026.

全球农药市场正在发生一场深层转变：法规收紧、传统活性成分加速退出、绿色植保需求持续升温——化学农药企业面临的压力有目共睹。与此同时，RNA生物农药这一被誉为继化学农药、微生物农药之后最具潜力的新一代植保技术，正在全球范围内从"实验室概念"加速走向真实产品。中国创新力量深度参与其中，并正在带着可落地的产业化成果走向行业视野。